Yazar "Akman, Tülay" için listeleme
-
Clinical and pathologic features of patients with rare ovarian tumors: Multi-center review of 167 patients by the anatolian society of medical oncology
Bilici, Ahmet; İnanç, Mevlüde; Ulaş, Arife; Akman, Tülay; Şeker, Mehmet; Babacan Akgül, Nalan; İnal, Ali; Bal, Öznur; Koral, Lokman; Sevinç, Alper; Tufan, Gülnihal; Elkıran, Emin Tamer; Ustaalioğlu Öven, Bala Başak; Yavuzşen, Tuğba; Alkış, Necati; Özkan, Metin; Gümüş, Mahmut (Asian Pacific Organization for Cancer Prevention, 2013)Background: Non-epithelial malignant ovarian tumors and clear cell carcinomas, Brenner tumors, transitional cell tumors, and carcinoid tumors of the ovary are rare ovarian tumors (ROTs). In this study, our aim was to ... -
The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey Molecular Profiling in Advanced Cancers Trial (TUMPACT)
Ölmez, Ömer Fatih; Bilici, Ahmet; Er, Özgür; Sevinç, Ali İbrahim; Akman, Tülay; Uslu, Rüçhan; Mandel, Nil Molinas; Yalçın, Şule; Teomete, Mehmet; Görümlü, Gürbüz; Demir, Ahmet Muzafer; Namal, Esat; Alıcı, Süleyman; Selçukbiricik, Fatih; Bavbek, Sevil; Paksoy, Fatma; Başaran, Gül; Özer, Leyla; Şener, Nazlı; Harputluoğlu, Hakan (Elsevier, 2020)Background: Molecular genetic profiling (MGP) which has started to take an important part in cancer diagnosis and treatment in recent years, has entered the routineclinical practice much faster than expected. We aimed to ... -
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
Yıldız, İbrahim; Bilici, Ahmet; Karadurmuş, Nuri; Özer, Leyla; Tural, Deniz; Kaplan, Mehmet Ali; Akman, Tülay; Bayoğlu, İbrahim Vedat; Uysal, Mükremin; Yıldız, Yaşar; Tanrıverdi, Özgür; Yazıcı, Ozan; Sürmeli, Zeki; Turhal, Nazim Serdar; Bavbek, Sevil; Selçukbiricik, Fatih; Koca, Doğan; Başaran, Mert (Sage Publications Ltd, 2018)Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and ...